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Human adenovirus (HAdV) infections are well-described after hematopoietic stem cell
transplantation but less well understood in solid organ transplantation (SOT). We
describe a case of disseminated HAdV type 21 infection 5 months after combined
liver-kidney transplantation, expanding the limited literature describing this infection in
the SOT population.
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INTRODUCTION
A patient with a history of end-stage liver disease due to alcoholic cirrhosis, complicated
by hepatorenal syndrome, underwent combined liver-kidney transplantation (CMV IgG
donor-positive, recipient-negative). The patient had received basiliximab induction; a panel of
reactive antibodies was 0/6. Initial post-transplant events included lysis of intraperitoneal adhesions
on post-transplant day 12, a urinary tract infection due to Raoultella spp. and a peri-hepatic
hematoma that became secondarily infected with Enterococcus gallinarum.
BACKGROUND
Five months after transplantation, the patient presented with acute onset of fevers, headache,
and fatigue. The patient specifically reported 3 days of a retro-orbital headache associated
with profound fatigue, anorexia, intermittent lower abdominal cramping without diarrhea, and
fevers to 38.5◦C. Importantly, during periods between fevers, the patient felt well with complete
but temporary resolution of symptoms. There was no report of recent travel; and hobbies
included woodworking and assisting in the church community. Immunosuppression included
tacrolimus, mycophenolate mofetil, and prednisone (15mg daily); antimicrobial prophylaxis
included valganciclovir 450mg daily.
Physical examination revealed no acute distress (blood pressure 110/63, pulse 69/min,
respiratory rate 16/min, temperature 36.8◦, oxygen saturation 97% on room air). The only
remarkable finding was minimal right lower quadrant tenderness with voluntary guarding but no
rebound sign. Laboratory analysis revealed leukopenia (1,700/mcl), creatinine 1.5 mg/dl (baseline
1.2–1.3 mg/dl), normal hepatobiliary enzymes, and tacrolimus level 6.1 ng/ml. Microscopic
examination of the urine showed 37 red blood cells and 2 white blood cells. Bacterial cultures
of urine and blood collected on different days were negative. Several initial viral studies were
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negative including a nasopharyngeal swab for an extended
respiratory viral panel (influenza A/B RNA, respiratory
syncytial virus (RSV) RNA, parainfluenza 1/2/3 RNA, human
metapneumovirus RNA, adenovirus DNA, and rhinovirus
RNA), serum cytomegalovirus (CMV) polymerase chain
reaction (PCR), and serum Epstein Barr Virus (EBV) PCR.
Lumbar puncture performed on day 3 of admission revealed a
normal opening pressure and no inflammatory cells; a viral PCR
panel was negative, including Human adenovirus (HAdV).
During the first five days of admission, the patient
experienced daily fevers to 39.3–39.4◦C. A chest x-ray and
Computed Tomography (CT) scans of the head, sinuses,
and abdomen/pelvis were unremarkable. Whole body Positron
Emission Tomography (PET)-CT indicated uptake in the
prostate and spleen (the latter thought to be secondary
to anemia). Initial treatment included piperacillin/tazobactam
and vancomycin without resolution of fevers, headache, or
fatigue. To minimize immunosuppression, mycophenolate was
discontinued.
PCR of the blood for HAdV performed on day 7 of his
admission was positive at 85,500 copies/ml, and urine HAdV
testing revealed 9.3 million copies/ml. Antibacterial agents were
discontinued, and the patient was treated with oral CMX-001
(brincidofovir), made available within 24 h through an expanded
access protocol. Informed consent was signed by the subject.
Because of broad anti-viral activity of brincidofovir against
double stranded DNA viruses, valganciclovir was discontinued
during treatment with CMX-001, and weekly serum CMV PCRs
were monitored for evidence of viral reactivation. The patient
tolerated the medication well, only reporting self-limited loose
stools on the first day of treatment. The fevers, headache and
fatigue resolved within 2 days, and the patient was discharged to
home 2 days after initiating CMX-001 (see Figures 1, 2).
After discharge, the patient remained afebrile and
asymptomatic. Serial HAdV serum and urine PCR testing
were performed: the serum PCR became negative on post-
treatment day 19, and the urine PCR became negative on day 48
(Figure 1). Twelve weeks of therapy were completed. During this
time, weekly PCR testing showed no evidence of CMV viremia.
Upon discontinuation of the CMX-001, the patient remained
well with no recurrent signs or symptoms of reactivation of
adenoviral infections. Weekly adenovirus and CMV PCRs of the
blood were performed for 4 weeks after cessation of CMX-001,
and all remained negative.
METHODS
Viral DNA was extracted from the patient’s urine specimen using
the Qiagen DNA blood Mini Kit (QIAGEN, Inc., Valencia, CA,
USA). Extracts were tested using previously described molecular
assays for the detection of both the hexon (Lu and Erdman, 2006)
and fiber (Xu et al., 2000; McCarthy et al., 2009) genes of HAdV.
Briefly, a one or two step Reverse Transcriptase Polymerase
Chain Reaction (RT-PCR) was performed using extracted DNA
and primer sets for fiber and hexon targets, respectively and
resolved on a 1% agarose gel stained with Apex Safe DNA Stain
(Genesee Scientific, Morrisville, NC, USA). Amplified product
from each molecular assay was submitted to Eton Bioscience
(Eton Bioscience, Inc., Raleigh, NC, USA) for sequencing. Using
BioEdit 7.1.9 (Ibis Biosciences, Carlsband, CA, USA) sequences
were aligned, edited, and then compared to the NCBI sequence
database using the BLAST application Table S1.
RESULTS
Results from the hexon and fiber RT-PCR assays demonstrated
that the patient’s urine sample was positive for HAdV.
Sequencing data for hexon and fiber gene segments revealed a
98–99% identity to HAdV 21.
DISCUSSION
Adenoviruses are double-stranded DNA viruses, typically
associated with self-limited disease during childhood. In many
patients, minimally symptomatic infections involve individual
organ systems including the respiratory tract, gastrointestinal
tract, urinary bladder, and the eyes. In contrast, infections
in immunocompromised patients can cause significant adverse
events, including disseminated infections and fatal outcomes.
Specifically, in SOT patients, HAdV can also be associated with
transplantation graft infections such as hepatitis, nephritis or
myocarditis, resulting in graft failure (Ison, 2006; Dawood et al.,
2014). As sites of disease vary by the type of transplanted organ
and HAdV strain, the epidemiology of these infections is still
poorly understood.
We report a case of disseminated HAdV type 21
infection presenting 5 months after combined liver-kidney
transplantation. Symptomatic HAdV infections are infrequently
reported in adult SOT recipients (Hofland et al., 2004; Ison,
2006; Kozlowski et al., 2011; Storsley and Gibson, 2011; Sujeet
et al., 2011; Dawood et al., 2014; Lachiewicz et al., 2014; Klein
et al., 2015; Mehta et al., 2015; Saliba et al., 2017). An exception
to this is the lung transplant population in whom community
acquired asymptomatic viremia secondary to HAdV are not
infrequent (Humar et al., 2006; Bridevaux et al., 2014), likely
due to the uniqueness of the graft being in direct exposure to
the outside environment. However, a more extensive literature
is available in the pediatric hematopoietic stem cell transplant
(HCT) population. There are no FDA-approved drugs for HAdV
infection.
A prospective study explored the incidence of HAdV
infections in different SOT populations, finding that 7.2% of
the SOT recipients (liver, kidney, heart, kidney-pancreas) were
viremic in the first year after transplant (Ison and Green, 2009).
Specifically, this represented 8.3% of the liver transplants and
6.5% of the kidney transplants. Overall, 58% of the patients
remained asymptomatic (Humar et al., 2005). When assessed for
viral subtyping, HAdV type 21 was not frequently identified in
the transplant population (Gray et al., 2007).
The patient described here had disseminated diseases on the
basis of the involvement of two or more organs and the presence
of viremia (Florescu and Hoffman, 2013). Clinical presentation
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FIGURE 1 | Duration of HAdV persistence in blood and urine as defined by quantitative PCR. HAdV, human adenovirus; X-axis, days; Y-axis, number of copies of
HAdV (log 10 scale).
FIGURE 2 | Clinical and Laboratory progression. N/A, not available; Temp, temperature in degree Celsius; WBC, white blood count in 109/l; Creat, creatinine in mg/dl;
AST, aspartate aminotransferase in U/l; ALT, alanine aminotransferase in U/l.
included fever, HAdV viremia, as well as a HAdV viruria that
was 10-fold higher than in blood. This could represent a different
infectious compartment, or secondary viremia after primary
viruria.
HAdV type 21 is associated with increased risk of severe
disease (Gray et al., 2007). This viral type commonly
results in respiratory tract infections and myocarditis, with
other less frequent syndromes including hepatitis, colitis,
hemorrhagic cystitis, tubulointerstitial nephritis, conjunctivitis
and meningoencephalitis (Florescu and Hoffman, 2013; Florescu
et al., 2013; Dawood et al., 2014). We believe that our patient
did not have involvement of any of these sites. Regarding
the known respiratory tropism of this specific HAdV subtype
(Gray et al., 2007), there were no respiratory symptoms, and
an extended respiratory viral panel as described above was
negative.
In transplant patients, HAdV disease can present as a primary
infection, reactivation of persistent latent HAdV, or donor-
derived infection. The incubation period after initial exposure is 2
days−2 weeks. Most cases of HAdV infection in renal transplant
patients occur in the first year after transplantation (Hofland
et al., 2004; Lynch and Kajon, 2016). Transmission from the
donor graft has been described previously (Kozlowski et al.,
2011) to the extent that some authors advocate for pre-transplant
donor and recipient screening similar to that performed for CMV
(Piatti, 2016). In our case, neither the patient’s liver nor kidney
demonstrated an increased uptake on the PET scan. We cannot
definitively exclude involvement of these transplanted organs,
as no tissue samples were collected. However, given the lack
of clinical evidence of liver or kidney infection, primary HAdV
infection from the community or reactivation seem to be the
most likely source of acquisition in this case.
The diagnosis in SOT recipients is often challenging.
HAdV can involve the graft only and is not always easily
detected with PCR techniques (Piatti, 2016), requiring specific
requests for immunohistochemical tissue stains. Additionally, the
presentation can vary as severity and organ/tissue predilection
can vary by HAdV type (Gray et al., 2007).
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The natural course of the disease and the severity of the
infection are variable. Graft dysfunction and loss can occur
(Storsley and Gibson, 2011; Sujeet et al., 2011; Saliba et al.,
2017), but data regarding the impact of HAdV on rejection are
inconsistent. Fatality rates in disseminated disease in SOT range
from 11 to 50% (Echavarría, 2008).
Unfortunately, there are no generally accepted treatment
guidelines for HAdV. In immunocompetent patients, the
infection is usually self-limiting. While clearance of the
infection has been described in immunocompromised patients,
the severity and potential complications in this population
warrant further investigation into treatment options (Hoffman,
2009). Early diagnosis and treatment might improve outcomes.
Reduction in immunosuppression often becomes necessary
for clearance and is generally the first step in addressing
treatment (Florescu et al., 2013; Patel et al., 2015). While
precise quantification of the degree of immunosuppression
in SOT recipients is an area of active investigation, it is
generally supported that viral activation is evidence of “over-
immunosuppression.” Cidofovir is active against HAdV, but
its low oral bioavailability and potential for nephrotoxicity are
major dose-limiting factors (Ganapathi et al., 2016; Guerra
Sanchez et al., 2018). CMX-001 is an orally bioavailable, lipid-
ester derivative of cidofovir with improved intracellular active
drug delivery. Nephrotoxicity is infrequent because it does not
accumulate in the kidney (Painter et al., 2012). Its use for
HAdV is currently restricted to investigational use under research
protocols (Lopez et al., 2018). A phase III study in children
has recently been completed. In that study, rapid declines in
HAdV viremia were observed in the majority of allo-HCT
patients treated with CMX-001. Survival was higher in patients
with virologic response. These differences were statistically
significant in adults and pediatric patients (Prasad et al., 2017).
Immunotherapy (Haidar and Singh, 2017) has been used in the
treatment of HAdV infection, mainly in pediatric HCT and in the
setting of hypogammaglobulinemia, but results are anecdotal.
CONCLUDING REMARKS
In summary, HAdV infection should be considered in adults
presenting with a febrile illness after SOT. Further studies
are needed to outline the best preventative and therapeutic
approaches as HAdV infection carries a high morbidity and
mortality in the immunocompromised host.
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